A1Lead compound
Depside · Umbilicaria hirsuta
The best-characterised compound in the portfolio. Published work reports ROS production,
apoptosis and modulation of Akt, Erk1/2 and p38 MAPK in HeLa cells, with a validated isolation
protocol giving high-purity material.
- Antiproliferative screening
- ROS / oxidative stress
- Apoptosis
- HeLa model
- Evidence
- Peer-reviewed 2019 · mechanistic dataset
- Stage
- Pilot-ready · licensing open
- Indicative
- € 8 000 – 35 000negotiable by scope and application
A2
Depsidone · Hypogymnia physodes
The strongest radical scavenger in our comparative metabolite study — and the comparison was
made per mole rather than per unit weight. That distinction matters when you translate a screening
result into a formulation dose.
- Antioxidant discovery
- Cosmetic actives
- Nutraceuticals
- Evidence
- Peer-reviewed 2022 · DPPH + superoxide
- Stage
- Pilot-ready · licensing open
- Indicative
- € 5 000 – 25 000negotiable by scope and application
A3
Depside · Reference metabolite
A widely cited lichen compound with repeatedly published bioactivity, included in both of our
screening studies. A dependable reference compound and panel anchor for antiproliferative,
antioxidant and antimicrobial work.
- Cytotoxicity
- Redox modulation
- Reference standard
- Evidence
- Peer-reviewed 2022 & 2023
- Stage
- Pilot-ready · licensing open
- Indicative
- € 4 000 – 22 000negotiable by scope and application
A4
Depsidone · Hypogymnia physodes
Present in both of our published panels, with antioxidant and antiproliferative activity
reported in 2D and 3D models. A natural comparator when you want to benchmark a candidate
against gyrophoric acid within one experimental system.
- Antioxidant
- Antiproliferative
- Panel candidate
- Evidence
- Peer-reviewed 2022 & 2023
- Stage
- Pilot-ready · licensing open
- Indicative
- € 5 000 – 25 000negotiable by scope and application
A6Research use only
Dibenzofuran · Benchmark compound
The standard reference metabolite for benchmarking cytotoxicity and antioxidant assays, and a
control compound in multi-metabolite panels. Supplied for research use only — significant
toxicological caution is required before any consumer positioning.
- Benchmark assay
- Research use
- Toxicological caution
- Evidence
- Peer-reviewed 2022 (comparative)
- Stage
- Pilot-ready · RUO material
- Indicative
- € 3 000 – 18 000negotiable by scope and application
A7Fastest entry point
Standardised crude / semi-purified extracts · 5–10 species
The quickest way to see what lichen chemistry can do for your pipeline. Panels of
Pseudevernia furfuracea, Lobaria pulmonaria, Cetraria islandica,
Umbilicaria hirsuta and related species, with HPLC/LC-MS profiling plus antioxidant,
antimicrobial and cell viability assays. You receive a shortlist of active candidates with data.
- Discovery screening
- Multi-species panel
- Antiproliferative
- Antimicrobial
- Antioxidant
- Lead fractionation
- Evidence
- Peer-reviewed 2023 · profiling data
- Stage
- Pilot-ready · 8–12 weeks
- Indicative
- € 8 000 – 40 000lead isolation quoted individually
B1Flagship platform
Protein engineering · Fibrinolytic variants
Rank hundreds of variants without purifying each one. A cell-free expression platform scores
staphylokinase variants by activity directly from unpurified reactions — built for engineering
campaigns where variant numbers make conventional screening impractical.
- Cell-free screening
- High-throughput ranking
- Protein engineering
- Evidence
- Publication reported 2026 · data package under NDA
- Stage
- Pilot-ready · co-development open
- Indicative
- € 12 000 – 60 000co-development quoted individually
B3
Protein biophysics · Formulation support
Know before you formulate. DSC, fluorescence probes and dynamic light scattering map
thermodynamic and kinetic stability; buffer, salt and pH screening and aggregation risk
profiling are run on your protein rather than on a generic prediction.
- Thermal stability
- Aggregation risk
- Buffer optimisation
- Evidence
- Method portfolio · report under NDA
- Stage
- Pilot-ready
- Indicative
- € 8 000 – 50 000negotiable by scope and application
B4
Protease activity · Condition optimisation
Kosmotropic anions increase HRV 3C protease rigidity, stability and catalytic efficiency — a
published finding with direct workflow consequences. If your production depends on a cleavage
step, this tells you which conditions maximise yield and enzyme lifetime.
- Protease workflow
- Salt screening
- Enzyme stability
- Evidence
- Peer-reviewed 2022 (Biophys. Chem.)
- Stage
- Pilot-ready
- Indicative
- € 6 000 – 35 000negotiable by scope and application
B5
Recombinant protein purification
One-step affinity purification and immobilisation for MBP-tagged proteins. The MBP tag
substantially improves solubility for difficult-to-express fusion partners — a cost-effective
alternative for teams spending too much on multi-step chromatography of insoluble targets.
- MBP tag
- Enhanced solubility
- One-step purification
- Evidence
- Method portfolio · report under NDA
- Stage
- Pilot-ready
- Indicative
- € 5 000 – 40 000negotiable by scope and application
B6
Membrane protein · GPCR
High-risk, high-reward targets made more tractable: candidate selection, expression and
purification strategy, hot-spot identification, and yeast or ribosome display for solubility
improvement. Feasibility first — before you commit a full GPCR budget.
- GPCR
- Membrane proteins
- Drug discovery
- Evidence
- Feasibility assessment · under NDA
- Stage
- Feasibility → pilot · licensing open
- Indicative
- € 15 000 – 120 000negotiable by scope and application
B7
Aggregation · Self-assembly
Aggregation quietly kills promising protein therapeutics and formulations. The platform screens
stress conditions, maps aggregation kinetics and identifies stabilisation strategies. It also
covers spider-silk self-assembly systems for biomedical and biomaterial applications.
- Aggregation assay
- Neurodegeneration research
- Advanced biomaterials
- Evidence
- Method portfolio · report under NDA
- Stage
- Pilot-ready · licensing open
- Indicative
- € 8 000 – 60 000negotiable by scope and application
C1Fluorescent probe
APF · C26H17NO5 · MW 433.42 g/mol
Cell-permeable, photostable probe for selective detection of highly reactive oxygen and
nitrogen species. On reaction with hROS/hRNS it is cleaved to release free fluorescein, giving a
strong signal on standard microscopes, flow cytometers and plate readers.
- hROS / hRNS detection
- Live-cell imaging
- Flow cytometry
- HCS antioxidant screening
- Selectivity
- OCl⁻ · HO· · ONOO⁻
- Stage
- Synthesis to order
- Indicative
- Price on requestby quantity and application
C2
NPF · C26H15NO7 · MW 463.40 g/mol
A substrate and reporter group for enzymatic and bioanalytical assays. Enzyme-mediated
hydrolysis or reduction of the nitrophenyl ester bond changes absorbance and fluorescence,
producing an optical signal proportional to enzyme activity or analyte concentration.
- Enzyme activity reporter
- Esterase substrates
- Hydrolase profiling
- Plate-reader compatible
- Readout
- Absorbance · fluorescence
- Stage
- Synthesis to order
- Indicative
- Price on requestby quantity and application
C3
Pyrrolidine-based sphingolipid analogues
Synthetic compounds designed to mimic the structure and function of natural sphingolipids. The
five-membered nitrogen heterocycle improves chemical stability and affinity for specific enzymes,
making these candidates for inhibitor development and lysosomal disorder research.
- Glucosylceramide synthase inhibitors
- Gaucher disease research
- Ceramide regulation
- Anticancer screening
- Evidence
- Synthetic capability · characterisation on request
- Stage
- Synthesis to order · licensing open
- Indicative
- Price on requestby quantity and application
C4
Sphingoid bases · D/L-ribo & D/L-arabino
Natural components of plants, yeasts and human skin. Four stereoisomers differ in the spatial
arrangement of hydroxyl groups, which makes the set useful for enzyme stereoselectivity studies.
D-ribo-phytosphingosine is the most common natural form.
- Cosmetics & dermatology
- Skin barrier
- Anti-acne research
- Enzyme stereoselectivity
- Evidence
- Synthetic capability · characterisation on request
- Stage
- Synthesis to order · licensing open
- Indicative
- Price on requestby quantity and application
C5
Amino derivatives · D-/L-erythro · –NH₂ at C3
Dihydrosphingosine derivatives in which the C3 hydroxyl is replaced by an amino group. The
D-erythro and L-erythro isomers show distinct biological activity, and the amino group enables
stronger protein kinase C inhibition — relevant to cell signalling and apoptosis research.
- Molecular probes
- PKC inhibition
- Apoptosis research
- Sphingolipid metabolism
- Evidence
- Synthetic capability · characterisation on request
- Stage
- Synthesis to order
- Indicative
- Price on requestby quantity and application
C6
Sphingosine analogues · S1P pathway
Sphingosine is the fundamental building block of sphingolipids. These analogues carry modified
chain lengths or functional groups for precise modulation of sphingosine-1-phosphate signalling —
a pathway studied in autoimmune disease and tumour angiogenesis research.
- S1P pathway modulation
- Multiple sclerosis research
- Angiogenesis research
- Biomedical research
- Evidence
- Synthetic capability · characterisation on request
- Stage
- Synthesis to order · licensing open
- Indicative
- Price on requestby quantity and application
C7Bioconjugation tools
Saccharide derivatives · Reactive intermediates
Sugar isothiocyanates form covalent bonds with amines, which makes them useful for conjugating
sugars to proteins or fluorescent labels and tracking sugar transport in vivo. Aminosugars are
building blocks for glycoprotein and glycolipid synthesis, joint-nutrition compounds and
antibiotic development targeting bacterial cell walls.
- Bioconjugation
- Glycoprotein synthesis
- Glycolipid building blocks
- Antibiotic development
- Chondroprotectives
- Evidence
- Synthetic capability · characterisation on request
- Stage
- Synthesis to order · licensing open
- Indicative
- Price on requestcustom quantities available
